This phase II study evaluated the efficacy and safety of combination chemotherapy with irinotecan, highdose 5-fluorouracil (5-FU), and leucovorin as a second line of treatment in metastatic gastric cancer refractory to taxane and cisplatin-based chemotherapy. Eligible criteria were as follows: histologically confirmed adenocarcinoma of the stomach previously treated with taxane and cisplatin, age≥18 years, Eastern Clinical Oncology Group (ECOG) performance status of 1 or less, and adequate organ function. Irinotecan (150 mg/m 2 ) and leucovorin (200 mg/m 2 ) were given on day 1, followed by a 400-mg/m 2 bolus infusion of 5-FU and then 2,400 mg/m 2 5-FU as a 48-hour continuous infusion. This cycle was repeated every 2 weeks until disease progression or unacceptable toxicities. Thirty-seven patients were enrolled. The patients' median age was 55 years (range, 27∼73 years), and the ECOG performance status of all patients was 1. All patients were evaluable for safety and survival, and 29 patients (78.3%) were evaluable for tumor response. The overall response rate was 17.2% [95% confidence interval (CI): 3.5∼30.9%]. The median progression-free survival and overall survival were 4.3 months (95% CI: 2.1∼6.6) and 10.6 months (95% CI: 7.1∼14.1). Greater than grade 3 hematological toxicities were neutropenia in 9 (24.3%), febrile neutropenia in 1 (2.7%), and thrombocytopenia in 1 (2.7%) patient. The major nonhematological toxicity was asthenia, but most patients showed grade 1 or 2. Greater than grade 3 nonhematological toxicities were elevated AST/ALT in 4 (10.8%), hyperbilirubinemia in 2 (5.4%), and nausea in 2 (5.4%) patients. This study showed that combination chemotherapy with irinotecan, high dose 5-FU, and leucovorin is well tolerated and active in patients with cancer refractory to taxane and cisplatin.
Introduction
Although the incidence and mortality of gastric cancer have decreased worldwide, gastric cancer remains the second leading cause of cancer mortality behind lung cancer. 1 Early detection and radical surgery have improved treatment outcomes of localized gastric cancer. In cases of unresectable advanced or recurrent gastric cancer, systemic chemotherapy has been recommended as a standard treatment, and its prolongation of survival or increase in the quality of life is well established. 
Dose modification
The subsequent cycle of chemotherapy was withheld if ANC ＜1,500/mm 3 or platelets ＜100,000/mm 3 was noted on the due day. Patients presenting with grade 3 or 4 hematologic toxicity restarted the treatment with a 25% dose reduction of all drugs. During the study, granulocyte colony-stimulating factor was allowed in patients with grade 4 neutropenia or febrile neutropenia.
In patients developing grade 2 diarrhea, treatment was restarted with a 25% dose reduction of irinotecan; in cases of grade 3 or 4 diarrhea, all drugs were reduced by 50%. Patients developing grade 2 mucositis received a 25% dose reduction of leucovorin and 5-FU; in case of grade 3 or 4 mucositis, leucovorin and 5-FU were restarted at a 50% dose reduction and irinotecan at 75%.
If drug administration was delayed more than 2 weeks, the patient was excluded from the study.
Pretreatment evaluation
Baseline evaluations included a full medical history, physical examination, ECOG performance status, CBC, serum chemistries, electrolytes, urinalysis, chest X-ray, electrocardiogram, and computed tomography (CT) scans.
Baseline evaluations were completed within 3 weeks before treatment. For females with child-bearing potential, a negative serum pregnancy test was also required. Gastroduodenoscopy and positron emission tomography were planned for the evaluation of complete responders of all evaluable lesions.
Evaluation during chemotherapy
History taking, physical examination, CBC, electrolytes, serum chemistry, urinalysis, and chest X-ray were repeated before the initiation of each subsequent cycle.
CT scans for evaluating response to treatment were per- 
Results

Patient characteristics
Thirty-seven patients were enrolled. Patient characteristics are summarized in Table 1 . The median age was 55 years, with a range of 27 to 73 years. Thirty-one patients were male (83.8%) and 6 were female (16.2%).
The ECOG performance status of all patients was one.
All patients had histologically confirmed adenocarcinoma.
Twenty patients (54.1%) had prior gastrectomy. Fifteen patients (40.5%) had recurrent disease after undergoing an operation and 22 patients (59.5%) had no prior operation because of initially distant metastasis. The most common metastatic site was the abdominal lymph nodes, followed by the peritoneum and liver.
Chemotherapy delivery
The median number of treatment cycles was 6, with a range from 1 to 19 cycles. Twenty patients received more than 6 cycles (54.1%). The median duration of treatment for all patients was 3.1 months, with a range of 0.5 to 12.8 months. The total number of cycles de- 
Efficacy
Among enrolled patients, 29 were evaluable for treatment response. Response could not be evaluated in 8 patients because of poor general condition (n=5), loss of follow-up (n=2), or in course of chemotherapy (n=1).
Among 29 evaluable patients, 1 (3.4%) showed CR and 4 (13.8%) showed PR, resulting in an ORR of 17.2%
(95% CI, 3.5∼30.9). Eight patients (27.6%) showed SD, resulting in a disease control rate (DCR) of 44.8% (95% CI, 26.7∼62.9) ( Table 2 ). The median duration of response was 4.8 months (range, 3.0∼6.0). Differences in response rates were not observed according to the patients' baseline characteristics (age, sex, involved organs, disease status, and previous chemotherapy regimen). Of 25 patients with measurable disease, 1 showed CR and 4 showed PR, giving an overall response rate of 20% in the intention-to-treat analysis. Of 4 patients with nonmeasurable disease, 2 patients showed SD and 2 patients showed PD.
Survival outcome
Of the 37 patients who were evaluated for survival outcome, 19 (51.4%) were alive at the time of analysis, and the median duration of follow-up was 6.8 months (95% CI, 3.9∼9.6). The median PFS and OS were 4.3 (95% CI: 2.1∼6.6) and 10.6 (95% CI, 7.1∼14.1) months, respectively (Fig. 1) . Survival was also calculated Table 3 . Chemotherapy-related toxicities in 37 patients from the first day of first-line chemotherapy (diagnostic date of metastatic gastric cancer or recurred gastric cancer) to the date of death or last follow-up. The median survival was 18.3 months (95% CI, 13.0∼23.6).
Toxicity
All patients were evaluable for safety. Chemotherapyrelated toxicities are summarized in Table 3 . The main hematological toxicity was neutropenia. Greater than grade 3 neutropenia developed in 9 patients (24.3%). 
